Abstract
A team led by Genmab has shown that IgG4-based therapeutic antibodies can exchange Fab arms with endogenous IgG4 antibodies. Unwanted biological consequences could potentially include the cases of progressive multifocal leukoencephalopathy seen with Tysabri natalizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
